Flex Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Flex Ltd trades at $120.17 (market cap $42.40B), while State Street SPDR S&P Biotech ETF trades at $153.72 (market cap $10.11B). The key difference: Flex Ltd is far larger — about 4.2× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Flex Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flex Ltd for 4 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FLEX | XBI | |
|---|---|---|
Market Cap | $42.40B | $10.11B |
Volume | 2,642,359 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $162.07 | $169.55 |
52-Week Low | $54.51 | $104.99 |
Typical Hold Time | 4 Days | 38 Days |
Enterprise Value | $45.49B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
Flex provides design, engineering, manufacturing, supply chain, and logistics services for technology products. It serves industries including cloud, data centers, communications, automotive, healthcare, and industrials.
Read more on FLEX →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →